Comparative Pharmacology
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus KEFLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus KEFLIN.
CEFTAROLINE FOSAMIL vs KEFLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
600 mg IV every 12 hours infused over 1 hour
1-2 g IV/IM every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-3 hours in anuria. Clinically, dosing every 6 hours is recommended.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Renal: 70-80% unchanged via glomerular filtration and tubular secretion; biliary: minimal (<5%); fecal: <1%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic